BioXcel Therapeutics Inc (NASDAQ:BTAI) shares gapped down before the market opened on Friday . The stock had previously closed at $33.40, but opened at $34.20. BioXcel Therapeutics shares last traded at $36.24, with a volume of 695,243 shares trading hands.
Several equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioXcel Therapeutics in a research report on Wednesday, February 5th. BMO Capital Markets reaffirmed a “positive” rating and set a $26.00 price objective on shares of BioXcel Therapeutics in a research report on Thursday, January 16th. Canaccord Genuity raised their price objective on shares of BioXcel Therapeutics from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, December 31st. BidaskClub raised shares of BioXcel Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Finally, SunTrust Banks assumed coverage on shares of BioXcel Therapeutics in a research report on Tuesday, November 12th. They set a “buy” rating and a $24.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $23.80.
The stock has a market cap of $618.59 million, a P/E ratio of -17.10 and a beta of 3.73. The firm’s 50-day moving average is $20.43 and its two-hundred day moving average is $10.79. The company has a quick ratio of 5.04, a current ratio of 5.04 and a debt-to-equity ratio of 0.03.
Institutional investors and hedge funds have recently modified their holdings of the stock. Rational Advisors LLC bought a new position in BioXcel Therapeutics during the third quarter valued at approximately $48,000. Strs Ohio raised its position in BioXcel Therapeutics by 431.3% during the third quarter. Strs Ohio now owns 8,500 shares of the company’s stock valued at $59,000 after acquiring an additional 6,900 shares in the last quarter. American International Group Inc. raised its position in shares of BioXcel Therapeutics by 14.2% in the fourth quarter. American International Group Inc. now owns 4,346 shares of the company’s stock valued at $63,000 after purchasing an additional 539 shares during the period. Barclays PLC raised its position in shares of BioXcel Therapeutics by 133.5% in the fourth quarter. Barclays PLC now owns 6,940 shares of the company’s stock valued at $101,000 after purchasing an additional 3,968 shares during the period. Finally, Game Plan Financial Advisors LLC bought a new position in shares of BioXcel Therapeutics in the fourth quarter valued at approximately $183,000. 23.57% of the stock is currently owned by hedge funds and other institutional investors.
BioXcel Therapeutics Company Profile (NASDAQ:BTAI)
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.